Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 20:12:712122.
doi: 10.3389/fimmu.2021.712122. eCollection 2021.

Broadly Neutralizing Antibodies for HIV-1 Prevention

Stephen R Walsh  1 , Michael S Seaman  2
Affiliations
Review

Broadly Neutralizing Antibodies for HIV-1 Prevention

Stephen R Walsh et al. Front Immunol. .

Abstract

Given the absence of an effective vaccine for protection against HIV-1 infection, passive immunization strategies that utilize potent broadly neutralizing antibodies (bnAbs) to block acquisition of HIV-1 are being rigorously pursued in the clinical setting. bnAbs have demonstrated robust protection in preclinical animal models, and several leading bnAb candidates have shown favorable safety and pharmacokinetic profiles when tested individually or in combinations in early phase human clinical trials. Furthermore, passive administration of bnAbs in HIV-1 infected individuals has resulted in prolonged suppression of viral rebound following interruption of combination antiretroviral therapy, and robust antiviral activity when administered to viremic individuals. Recent results from the first efficacy trials testing repeated intravenous administrations of the anti-CD4 binding site bnAb VRC01 have demonstrated positive proof of concept that bnAb passive immunization can confer protection against HIV-1 infection in humans, but have also highlighted the considerable barriers that remain for such strategies to effectively contribute to control of the epidemic. In this review, we discuss the current status of clinical studies evaluating bnAbs for HIV-1 prevention, highlight lessons learned from the recent Antibody Mediated Prevention (AMP) efficacy trials, and provide an overview of strategies being employed to improve the breadth, potency, and durability of antiviral protection.

Keywords: Fc effector function; HIV-1; antibody; clinical trial; neutralizing.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. World Health Organization . Data and Statistics. Geneva, Switzerland: World Health Organization; (2020).
    1. Casadevall A, Dadachova E, Pirofski LA. Passive Antibody Therapy for Infectious Diseases. Nat Rev Microbiol (2004) 2:695–703. 10.1038/nrmicro974 - DOI - PubMed
    1. Graham BS, Ambrosino DM. History of Passive Antibody Administration for Prevention and Treatment of Infectious Diseases. Curr Opin HIV AIDS (2015) 10:129–34. 10.1097/COH.0000000000000154 - DOI - PMC - PubMed
    1. Walker LM, Burton DR. Passive Immunotherapy of Viral Infections: ‘Super-Antibodies’ Enter the Fray. Nat Rev Immunol (2018) 18:297–308. 10.1038/nri.2017.148 - DOI - PMC - PubMed
    1. Kumar D, Gauthami S, Bayry J, Kaveri SV, Hegde NR. Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond. Monoclon Antib Immunodiagn Immunother (2021) 40:36–49. 10.1089/mab.2021.0004 - DOI - PubMed

Publication types

MeSH terms